Use of immunomodulation methods in combination with cytokine fusions for disease treatment
AssigneeMedicenna Therapeutics Inc.
InventorFahar Merchant
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating a cancer comprising administering: a) an IL-4 receptor targeted cargo protein or an IL-13 receptor targeted cargo protein; and b) immunomodulatory agent (e.g., an IL-2 mutein or IL-2 mutein fusion protein described herein). Such combination therapies are particularly useful for the treatment of cancers that overexpress IL-4R or IL-13Rα2. Also provided herein are composition for use with the subject methods. Aspects of the methods and compositions are further detailed below.
Claims36
A method of treating a cancer in a patient in need thereof comprising administering to the patient:
- a) an IL-4 receptor targeted cargo protein or an IL-13 receptor targeted cargo protein;
- and
- b) an immunomodulatory agent,
- wherein the IL-4 receptor targeted cargo protein comprises an IL-4, IL-13, or IL-4 mutein, or an IL-13 mutein linked to a cargo moiety,
- wherein the IL-13 receptor targeted cargo protein comprises an IL-4, IL-13, an IL-4 mutein, or an IL-13 mutein linked to a cargo moiety,
- wherein the cargo moiety is capable of inhibiting cancer cell growth or killing cancer cells.
A composition comprising:
- a) an IL-4 receptor targeted cargo protein or an IL-13 receptor targeted cargo protein;
- and
- b) an immunomodulatory agent,
- wherein the IL-4 receptor targeted cargo protein comprises an IL-4, an IL-13, an IL-4 mutein, or an IL-13 mutein linked to a cargo moiety,
- wherein the IL-13 receptor targeted cargo protein comprises an IL-4, an IL-13, an IL-4 mutein, or an IL-13 mutein linked to a cargo moiety, and
- wherein the cargo moiety is capable of inhibiting cancer cell growth or killing cancer cells.
Dependencies are inferred from the claim text.